Opdivo® (nivolumab) – Expanded indication
October 13, 2023 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.
Download PDF
